data_1ag4_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1ag4 _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.48 -0.563 . . . . 5.7999999999999998 109.48 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 12.4 p -161.08 170.67 20.01 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.245 -0.909 . . . . 2.9100000000000001 109.597 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.507 ' CG2' HG23 ' A' ' 35' ' ' VAL . 4.7 t -85.69 165.17 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.298 -0.877 . . . . 1.98 109.409 179.906 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -116.67 115.92 26.57 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.273 -0.892 . . . . 1.1499999999999999 109.527 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.515 ' HD3' ' N ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -72.89 154.51 40.55 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.225 -0.922 . . . . 2.52 109.315 179.87 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.515 ' N ' ' HD3' ' A' ' 5' ' ' LYS . . . 95.59 100.19 1.82 Allowed Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.161 -1.576 . . . . 0.42999999999999999 109.161 -179.639 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.577 ' HB ' ' CD2' ' A' ' 17' ' ' PHE . 4.1 m -92.5 173.0 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.242 -1.152 . . . . 1.1599999999999999 109.913 -179.624 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 3.6 t -111.22 -156.18 0.58 Allowed 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.441 -0.787 . . . . 2.2599999999999998 109.454 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -56.12 -68.48 1.67 Allowed Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.46 -1.456 . . . . 2.3999999999999999 109.46 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -145.32 139.49 15.04 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.258 -1.142 . . . . 4.0599999999999996 109.432 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.576 ' HB3' ' CE1' ' A' ' 17' ' ' PHE . 36.1 Cg_endo -78.45 141.07 17.57 Favored 'Trans proline' 0 C--N 1.311 -1.396 0 C-N-CA 122.443 2.095 . . . . 2.9399999999999999 110.634 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . 0.546 ' N ' ' HB2' ' A' ' 15' ' ' GLU . . . -148.49 173.28 13.28 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.395 -0.816 . . . . 1.8600000000000001 109.595 179.681 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.515 ' HE3' ' CB ' ' A' ' 12' ' ' ALA . 0.0 OUTLIER 43.44 91.73 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.281 -0.887 . . . . 4.21 110.37 179.613 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.528 ' HA2' ' CG2' ' A' ' 57' ' ' THR . . . 47.04 34.06 7.35 Favored Glycine 0 N--CA 1.493 2.465 0 N-CA-C 110.863 -0.895 . . . . 0.73999999999999999 110.863 178.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.546 ' HB2' ' N ' ' A' ' 12' ' ' ALA . 47.5 mt-10 -116.56 137.64 52.02 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.864 -1.374 . . . . 2.0600000000000001 109.588 179.406 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.444 HG23 HG23 ' A' ' 53' ' ' VAL . 43.1 t -134.13 133.19 55.91 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.39 -0.819 . . . . 1.0900000000000001 109.467 -179.922 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.577 ' CD2' ' HB ' ' A' ' 7' ' ' VAL . 10.3 m-30 -107.19 111.79 24.36 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.315 -0.865 . . . . 2.1099999999999999 109.526 179.892 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.503 ' O ' ' CD1' ' A' ' 19' ' ' TYR . 4.9 mp -82.95 163.86 20.78 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.273 -0.892 . . . . 1.3100000000000001 109.155 179.663 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . 0.503 ' CD1' ' O ' ' A' ' 18' ' ' LEU . 13.8 m-85 -147.48 112.77 5.56 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.198 -0.938 . . . . 2.27 109.928 -179.659 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.567 ' HD3' ' CD2' ' A' ' 21' ' ' HIS . 15.8 tttt -46.33 141.78 3.31 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.285 -0.884 . . . . 2.98 108.762 179.379 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' HIS . . . . . 0.567 ' CD2' ' HD3' ' A' ' 20' ' ' LYS . 12.5 m-70 64.09 166.35 0.15 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.102 -0.998 . . . . 0.87 109.003 -179.647 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.539 ' CG2' ' ND2' ' A' ' 23' ' ' ASN . 33.9 m -82.65 -177.82 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.165 -0.959 . . . . 1.4199999999999999 110.422 -179.432 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.539 ' ND2' ' CG2' ' A' ' 22' ' ' VAL . 10.5 p30 40.8 51.8 3.14 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.809 -0.557 . . . . 2.3100000000000001 110.569 179.601 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.566 ' CE1' ' HD2' ' A' ' 52' ' ' LYS . 3.0 m-85 35.55 49.29 0.5 Allowed 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.628 -0.67 . . . . 3.75 110.625 179.085 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . 0.47 ' O ' ' HB2' ' A' ' 21' ' ' HIS . 7.5 tt0 -108.04 71.95 0.83 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.946 -1.096 . . . . 2.0699999999999998 109.5 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 161.3 -179.25 36.84 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.46 -1.456 . . . . 0.55000000000000004 109.46 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.578 ' HB3' ' CZ3' ' A' ' 29' ' ' TRP . 5.4 m-20 -52.39 163.03 0.45 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.266 -1.138 . . . . 1.6599999999999999 109.465 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' SER . . . . . 0.499 ' CB ' HG12 ' A' ' 7' ' ' VAL . 9.0 p -124.02 139.55 53.84 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.253 -0.904 . . . . 0.70999999999999996 109.759 -179.796 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' TRP . . . . . 0.578 ' CZ3' ' HB3' ' A' ' 27' ' ' ASP . 2.3 m-90 -115.4 149.75 37.48 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.271 -0.893 . . . . 4.75 109.496 179.86 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.508 ' CE ' HG22 ' A' ' 32' ' ' THR . 0.1 OUTLIER -118.71 118.7 32.34 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.244 -0.91 . . . . 2.1400000000000001 109.723 -179.75 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.487 ' CG1' HG22 ' A' ' 35' ' ' VAL . 1.8 t -126.5 115.85 43.35 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.339 -0.85 . . . . 1.3300000000000001 109.284 179.675 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' THR . . . . . 0.508 HG22 ' CE ' ' A' ' 30' ' ' LYS . 3.4 p -114.11 39.97 2.61 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.248 -0.907 . . . . 2.02 109.153 179.752 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.509 ' N ' HG23 ' A' ' 97' ' ' VAL . . . -154.68 -112.32 0.44 Allowed Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.502 -1.439 . . . . 2.6899999999999999 109.502 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.433 ' ND2' ' O ' ' A' ' 33' ' ' GLY . 11.5 m120 -138.68 140.57 38.85 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.368 -1.078 . . . . 1.8500000000000001 108.972 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.507 HG23 ' CG2' ' A' ' 3' ' ' VAL . 41.0 t -146.93 100.15 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.02 -1.05 . . . . 1.6299999999999999 109.809 -179.829 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . 0.471 ' O ' ' O ' ' A' ' 37' ' ' ASP . 4.2 p90 -105.66 150.87 25.05 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.224 -0.922 . . . . 4.9400000000000004 109.058 179.62 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.471 ' O ' ' O ' ' A' ' 36' ' ' TYR . 1.4 m-20 48.5 96.93 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.148 -0.97 . . . . 1.2 109.303 -179.812 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.591 ' CZ ' HG21 ' A' ' 92' ' ' ILE . 1.7 p90 -106.63 46.63 0.92 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.182 -0.949 . . . . 5.6600000000000001 109.925 -179.603 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.528 ' HA ' ' CB ' ' A' ' 45' ' ' ASN . 22.9 ptt180 -82.67 -41.22 19.65 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.134 -0.979 . . . . 4.4000000000000004 109.655 179.871 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' SER . . . . . 0.469 ' N ' ' HG3' ' A' ' 39' ' ' ARG . 0.9 OUTLIER -112.01 59.24 0.63 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.078 -1.014 . . . . 2.29 109.627 179.974 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.519 ' O ' ' CG1' ' A' ' 41' ' ' VAL . 74.3 t -105.49 8.34 9.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.145 -0.972 . . . . 1.53 109.706 -179.873 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 65.39 79.34 0.25 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.137 -0.977 . . . . 2.1000000000000001 109.578 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . 0.573 ' O ' ' CZ2' ' A' ' 29' ' ' TRP . . . 82.31 74.99 1.16 Allowed Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.861 -1.295 . . . . 1.8400000000000001 109.861 179.815 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . 0.53 ' HA ' ' CG2' ' A' ' 47' ' ' VAL . 16.2 tp 178.61 -45.61 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.157 -1.202 . . . . 2.2999999999999998 109.672 179.777 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . 0.558 ' O ' ' CB ' ' A' ' 46' ' ' ASP . 17.8 p-10 -46.49 131.42 11.01 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.045 -1.035 . . . . 2.1400000000000001 109.725 -179.76 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . 0.558 ' CB ' ' O ' ' A' ' 45' ' ' ASN . 0.7 OUTLIER 82.6 -45.43 0.15 Allowed 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.573 -0.704 . . . . 2.21 110.603 179.293 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.53 ' CG2' ' HA ' ' A' ' 44' ' ' LEU . 15.4 m -78.4 89.02 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 120.993 -1.067 . . . . 1.6899999999999999 110.193 -179.301 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.516 ' CG1' HG23 ' A' ' 92' ' ' ILE . 0.1 OUTLIER -160.4 102.99 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.371 -0.83 . . . . 2.0600000000000001 108.839 179.59 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' SER . . . . . 0.48 ' HB3' ' CG1' ' A' ' 22' ' ' VAL . 0.4 OUTLIER -139.34 -60.36 0.56 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.024 -1.048 . . . . 1.3300000000000001 110.741 -179.34 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.481 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 56.7 p -95.02 130.2 41.79 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.841 -1.162 . . . . 1.1000000000000001 109.95 -179.157 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.471 HG12 ' HG ' ' A' ' 18' ' ' LEU . 2.3 t -135.57 156.88 38.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.235 -0.916 . . . . 1.4199999999999999 109.36 179.8 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . 0.566 ' HD2' ' CE1' ' A' ' 24' ' ' PHE . 3.8 mtpt -134.85 119.0 17.58 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.164 -0.96 . . . . 2.0800000000000001 109.577 -179.86 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.469 ' O ' ' HB2' ' A' ' 77' ' ' SER . 57.6 t -90.65 145.63 7.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.146 -0.971 . . . . 1.25 109.349 179.811 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.463 ' O ' ' HA ' ' A' ' 77' ' ' SER . . . -78.74 167.61 53.0 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.795 -1.322 . . . . 0.51000000000000001 109.795 -179.818 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.425 ' O ' ' C ' ' A' ' 56' ' ' ASN . 35.3 Cg_endo -76.97 173.96 13.63 Favored 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 122.701 2.268 . . . . 0.81000000000000005 110.307 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . 0.425 ' C ' ' O ' ' A' ' 55' ' ' PRO . 0.7 OUTLIER 43.63 26.86 0.13 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.261 -0.899 . . . . 2.5800000000000001 109.285 -179.782 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.528 ' CG2' ' HA2' ' A' ' 14' ' ' GLY . 65.8 m -131.03 169.29 16.05 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.358 -0.839 . . . . 1.6599999999999999 109.382 -179.563 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.507 ' CG ' ' HA ' ' A' ' 75' ' ' GLU . 4.6 tttt -138.25 99.39 3.85 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.175 -0.953 . . . . 2.1099999999999999 108.911 179.642 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.453 ' O ' ' HB2' ' A' ' 74' ' ' LEU . . . -91.77 129.07 37.81 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.237 -0.915 . . . . 1.0900000000000001 110.042 -179.32 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.486 ' CD1' ' O ' ' A' ' 58' ' ' LYS . 0.0 OUTLIER -116.13 115.25 25.71 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.359 -0.838 . . . . 2.2000000000000002 109.38 179.767 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.584 ' CG1' ' CD1' ' A' ' 72' ' ' ILE . 40.1 pt -99.26 144.66 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.266 -0.896 . . . . 1.52 109.107 179.8 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . 0.536 ' CE2' ' HB2' ' A' ' 71' ' ' PHE . 9.0 m-85 -116.7 102.33 9.34 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.262 -0.899 . . . . 2.25 109.838 -179.627 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . 0.46 ' O ' ' HB2' ' A' ' 64' ' ' ASP . 19.8 tttt -48.93 141.08 8.06 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.194 -0.941 . . . . 3.5 108.75 179.641 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.517 ' N ' ' OG ' ' A' ' 93' ' ' SER . 0.1 OUTLIER 72.25 166.07 0.3 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.399 -0.813 . . . . 1.4199999999999999 109.133 -179.561 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' ASP . . . . . 0.472 ' O ' ' O ' ' A' ' 68' ' ' ASN . 2.6 m-20 -43.07 142.1 1.03 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.351 -0.843 . . . . 2.0 109.33 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . 0.453 ' HB2' ' CB ' ' A' ' 94' ' ' SER . 0.0 OUTLIER -54.68 -18.44 4.59 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.006 -1.059 . . . . 3.23 109.528 -179.884 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -74.01 -38.13 64.18 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.185 -0.947 . . . . 3.3100000000000001 109.947 -179.746 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' ASN . . . . . 0.472 ' O ' ' O ' ' A' ' 65' ' ' ASP . 5.0 m-20 -140.01 171.76 13.73 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.025 -1.047 . . . . 1.8400000000000001 109.688 -179.809 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . 0.438 ' HA3' ' HB2' ' A' ' 64' ' ' ASP . . . 115.45 -122.82 5.71 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.495 -1.442 . . . . 0.71999999999999997 109.495 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.474 ' O ' ' HA ' ' A' ' 62' ' ' PHE . 9.7 t-20 -147.02 164.78 31.9 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.213 -1.169 . . . . 2.5800000000000001 109.508 179.876 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . 0.541 ' C ' ' CD1' ' A' ' 71' ' ' PHE . 14.3 p90 -129.23 149.32 51.08 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.308 -0.87 . . . . 2.29 109.851 -179.692 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.584 ' CD1' ' CG1' ' A' ' 61' ' ' ILE . 44.4 pt -144.91 145.89 20.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.319 -0.863 . . . . 2.0299999999999998 109.095 179.48 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -106.52 143.43 34.63 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.247 -0.908 . . . . 3.1600000000000001 110.007 -179.454 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . 0.453 ' HB2' ' O ' ' A' ' 59' ' ' ALA . 3.7 mt -131.6 96.59 4.0 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.714 -0.847 . . . . 2.2599999999999998 108.714 179.6 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . 0.549 ' O ' ' CG ' ' A' ' 76' ' ' GLU . 12.7 pt-20 -71.72 167.93 18.85 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.275 -0.89 . . . . 2.0800000000000001 110.019 -179.426 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . 0.549 ' CG ' ' O ' ' A' ' 75' ' ' GLU . 7.3 pt-20 47.59 179.98 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.696 0 CA-C-O 121.554 0.692 . . . . 2.1600000000000001 110.306 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' SER . . . . . 0.469 ' HB2' ' O ' ' A' ' 53' ' ' VAL . 85.7 p -62.91 -173.18 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.42 -0.8 . . . . 1.8999999999999999 109.827 -179.578 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' SER . . . . . 0.456 ' OG ' ' HB ' ' A' ' 53' ' ' VAL . 79.1 p -179.89 161.61 0.98 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.42 -0.8 . . . . 1.3799999999999999 109.33 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -135.24 94.58 3.14 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.223 -0.923 . . . . 2.2599999999999998 109.859 -179.807 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.539 ' CG1' ' CD2' ' A' ' 83' ' ' LEU . 54.4 t -94.71 71.26 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 O-C-N 121.381 -0.824 . . . . 1.3799999999999999 109.203 179.72 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.459 ' O ' ' HB ' ' A' ' 22' ' ' VAL . 0.0 OUTLIER -59.01 -34.0 71.37 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.475 -0.765 . . . . 1.3400000000000001 110.214 -179.568 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . 0.437 ' OD1' HG12 ' A' ' 22' ' ' VAL . 0.1 OUTLIER -127.74 141.01 51.71 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.041 -1.037 . . . . 2.1899999999999999 110.184 -179.468 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.539 ' CD2' ' CG1' ' A' ' 80' ' ' VAL . 21.3 mt -126.43 21.31 7.23 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.412 -0.805 . . . . 1.47 109.342 179.609 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' THR . . . . . 0.532 ' CG2' ' OD1' ' A' ' 89' ' ' ASN . 1.2 p -59.96 -44.23 94.54 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.233 -0.917 . . . . 3.23 109.523 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 16.3 p -61.93 -32.15 72.54 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.305 -0.872 . . . . 5.9699999999999998 109.538 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . 0.507 ' HA ' ' NE ' ' A' ' 86' ' ' ARG . 0.0 OUTLIER -71.0 -42.08 70.09 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.218 -0.926 . . . . 6.2199999999999998 109.739 -179.75 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.479 ' HB2' ' O ' ' A' ' 86' ' ' ARG . 19.9 t-20 172.2 66.11 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.142 -0.974 . . . . 4.1600000000000001 109.921 179.887 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.476 ' O ' ' O ' ' A' ' 87' ' ' ASN . 0.1 OUTLIER 57.67 116.08 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.233 -0.917 . . . . 2.6899999999999999 109.893 179.551 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . 0.532 ' OD1' ' CG2' ' A' ' 84' ' ' THR . 0.3 OUTLIER -45.88 162.33 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.218 -0.926 . . . . 2.46 109.6 179.76 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . 0.51 ' O ' ' CB ' ' A' ' 91' ' ' ALA . 33.9 m-20 61.65 134.61 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.071 -1.018 . . . . 1.22 109.637 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.51 ' CB ' ' O ' ' A' ' 90' ' ' ASP . . . 75.91 35.79 0.48 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.192 -0.943 . . . . 1.3100000000000001 110.092 179.62 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.591 HG21 ' CZ ' ' A' ' 38' ' ' PHE . 0.1 OUTLIER -45.48 -90.91 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 120.96 -1.087 . . . . 1.6899999999999999 108.883 179.591 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' SER . . . . . 0.535 ' N ' ' CG1' ' A' ' 92' ' ' ILE . 0.4 OUTLIER 174.69 -83.33 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.815 -1.178 . . . . 1.77 109.833 179.546 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' SER . . . . . 0.468 ' HB3' ' HA ' ' A' ' 36' ' ' TYR . 4.4 m -143.22 145.69 33.0 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.29 -0.881 . . . . 0.98999999999999999 109.525 -179.673 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -132.5 134.19 59.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.333 -0.854 . . . . 1.3799999999999999 109.383 179.792 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . 0.497 HG21 ' N ' ' A' ' 97' ' ' VAL . 22.5 mt -120.52 146.82 24.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.475 0 O-C-N 121.285 -0.884 . . . . 1.1299999999999999 109.312 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.516 ' O ' ' CG2' ' A' ' 97' ' ' VAL . 2.5 m -116.89 118.85 60.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.178 -0.951 . . . . 1.8200000000000001 109.423 179.862 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -140.47 129.85 23.9 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.232 -0.918 . . . . 1.0900000000000001 109.578 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 80.2 p -75.73 168.54 19.83 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.203 -0.936 . . . . 1.1899999999999999 109.528 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 38.4 t80 -80.47 141.43 35.23 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.346 -0.846 . . . . 5.2599999999999998 109.518 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.414 ' O ' ' C ' ' A' ' 102' ' ' SER . 0.4 OUTLIER -158.93 155.84 28.39 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.292 -0.88 . . . . 5.04 109.449 179.973 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.414 ' C ' ' O ' ' A' ' 101' ' ' GLU . 7.3 p -44.49 145.17 0.89 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.261 -0.899 . . . . 6.0599999999999996 109.424 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.504 0 CA-C-O 117.983 -1.008 . . . . 6.9699999999999998 109.472 -179.961 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.48 -0.563 . . . . 5.48 109.48 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 12.4 p -161.08 170.67 20.01 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.245 -0.909 . . . . 2.46 109.597 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.876 ' CG1' HG22 ' A' ' 31' ' ' VAL . 4.7 t -85.69 165.17 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.298 -0.877 . . . . 1.39 109.409 179.906 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.417 ' N ' HG12 ' A' ' 3' ' ' VAL . 0.7 OUTLIER -116.67 115.92 26.57 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.273 -0.892 . . . . 0.84 109.527 -179.944 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.511 ' HD3' ' N ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -72.89 154.51 40.55 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.225 -0.922 . . . . 1.99 109.315 179.87 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.511 ' N ' ' HD3' ' A' ' 5' ' ' LYS . . . 95.59 100.19 1.82 Allowed Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.161 -1.576 . . . . 0.42 109.161 -179.639 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.691 HG13 ' OG ' ' A' ' 28' ' ' SER . 4.1 m -92.5 173.0 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.242 -1.152 . . . . 0.57 109.913 -179.624 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 3.6 t -111.22 -156.18 0.58 Allowed 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.441 -0.787 . . . . 1.82 109.454 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -56.12 -68.48 1.67 Allowed Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.46 -1.456 . . . . 2.4 109.46 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 14.4 p-10 -145.32 139.49 15.04 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.258 -1.142 . . . . 4.06 109.432 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.577 ' HB3' ' CD1' ' A' ' 17' ' ' PHE . 36.1 Cg_endo -78.45 141.07 17.57 Favored 'Trans proline' 0 C--N 1.311 -1.396 0 C-N-CA 122.443 2.095 . . . . 2.55 110.634 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ALA . . . . . 0.933 ' HB1' ' HE3' ' A' ' 13' ' ' LYS . . . -148.49 173.28 13.28 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.395 -0.816 . . . . 1.35 109.595 179.681 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.933 ' HE3' ' HB1' ' A' ' 12' ' ' ALA . 0.0 OUTLIER 43.44 91.73 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.281 -0.887 . . . . 3.78 110.37 179.613 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.619 ' HA2' HG23 ' A' ' 57' ' ' THR . . . 47.04 34.06 7.35 Favored Glycine 0 N--CA 1.493 2.465 0 N-CA-C 110.863 -0.895 . . . . 0.54 110.863 178.963 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.567 ' HB2' ' N ' ' A' ' 12' ' ' ALA . 47.5 mt-10 -116.56 137.64 52.02 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.864 -1.374 . . . . 2.06 109.588 179.406 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 43.1 t -134.13 133.19 55.91 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.39 -0.819 . . . . 0.31 109.467 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.586 ' CD2' ' HB ' ' A' ' 7' ' ' VAL . 10.3 m-30 -107.19 111.79 24.36 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.315 -0.865 . . . . 1.26 109.526 179.892 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.903 HD11 HD13 ' A' ' 95' ' ' ILE . 4.9 mp -82.95 163.86 20.78 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.273 -0.892 . . . . 0.67 109.155 179.663 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' TYR . . . . . 0.525 ' HB3' ' HA ' ' A' ' 24' ' ' PHE . 13.8 m-85 -147.48 112.77 5.56 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.198 -0.938 . . . . 1.4 109.928 -179.659 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.643 ' HE3' HG11 ' A' ' 47' ' ' VAL . 15.8 tttt -46.33 141.78 3.31 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.285 -0.884 . . . . 2.43 108.762 179.379 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' HIS . . . . . 0.561 ' CD2' ' HD3' ' A' ' 20' ' ' LYS . 12.5 m-70 64.09 166.35 0.15 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.102 -0.998 . . . . 0.76 109.003 -179.647 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 1.066 HG23 ' ND2' ' A' ' 23' ' ' ASN . 33.9 m -82.65 -177.82 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.165 -0.959 . . . . 0.77 110.422 -179.432 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 1.066 ' ND2' HG23 ' A' ' 22' ' ' VAL . 10.5 p30 40.8 51.8 3.14 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.809 -0.557 . . . . 2.15 110.569 179.601 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.556 ' CE1' ' HD2' ' A' ' 52' ' ' LYS . 3.0 m-85 35.55 49.29 0.5 Allowed 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.628 -0.67 . . . . 2.93 110.625 179.085 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLN . . . . . 0.496 ' HB2' ' OD1' ' A' ' 23' ' ' ASN . 7.5 tt0 -108.04 71.95 0.83 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.946 -1.096 . . . . 1.73 109.5 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 161.3 -179.25 36.84 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.46 -1.456 . . . . 0.5 109.46 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.605 ' HB3' ' CZ3' ' A' ' 29' ' ' TRP . 5.4 m-20 -52.39 163.03 0.45 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.266 -1.138 . . . . 1.66 109.465 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' SER . . . . . 0.691 ' OG ' HG13 ' A' ' 7' ' ' VAL . 9.0 p -124.02 139.55 53.84 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.253 -0.904 . . . . 0.46 109.759 -179.796 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' TRP . . . . . 0.605 ' CZ3' ' HB3' ' A' ' 27' ' ' ASP . 2.3 m-90 -115.4 149.75 37.48 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.271 -0.893 . . . . 3.71 109.496 179.86 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -118.71 118.7 32.34 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.244 -0.91 . . . . 1.67 109.723 -179.75 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.876 HG22 ' CG1' ' A' ' 3' ' ' VAL . 1.8 t -126.5 115.85 43.35 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.339 -0.85 . . . . 0.69 109.284 179.675 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.506 ' CG2' ' HG2' ' A' ' 15' ' ' GLU . 3.4 p -114.11 39.97 2.61 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.248 -0.907 . . . . 1.62 109.153 179.752 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.77 ' O ' HG22 ' A' ' 97' ' ' VAL . . . -154.68 -112.32 0.44 Allowed Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.502 -1.439 . . . . 2.05 109.502 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.432 ' OD1' HG23 ' A' ' 96' ' ' ILE . 47.6 m-20 -138.68 140.57 38.85 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.368 -1.078 . . . . 1.85 108.972 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.726 HG21 HG22 ' A' ' 3' ' ' VAL . 41.0 t -146.93 100.15 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.02 -1.05 . . . . 1.11 109.809 -179.829 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' TYR . . . . . 0.471 ' O ' ' O ' ' A' ' 37' ' ' ASP . 4.2 p90 -105.66 150.87 25.05 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.224 -0.922 . . . . 4.46 109.058 179.62 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.471 ' O ' ' O ' ' A' ' 36' ' ' TYR . 1.4 m-20 48.5 96.93 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.148 -0.97 . . . . 1.2 109.303 -179.812 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.624 ' CE2' HG23 ' A' ' 92' ' ' ILE . 1.7 p90 -106.63 46.63 0.92 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.182 -0.949 . . . . 4.62 109.925 -179.603 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.537 ' HA ' ' CB ' ' A' ' 45' ' ' ASN . 22.9 ptt180 -82.67 -41.22 19.65 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.134 -0.979 . . . . 3.77 109.655 179.871 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' SER . . . . . 0.485 ' N ' ' HG3' ' A' ' 39' ' ' ARG . 0.9 OUTLIER -112.01 59.24 0.63 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.078 -1.014 . . . . 1.97 109.627 179.974 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.736 ' O ' HG12 ' A' ' 41' ' ' VAL . 74.3 t -105.49 8.34 9.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.145 -0.972 . . . . 1.21 109.706 -179.873 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 65.39 79.34 0.25 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.137 -0.977 . . . . 2.08 109.578 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' GLY . . . . . 0.573 ' O ' ' CZ2' ' A' ' 29' ' ' TRP . . . 82.31 74.99 1.16 Allowed Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.861 -1.295 . . . . 1.77 109.861 179.815 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.536 ' HA ' ' CG2' ' A' ' 47' ' ' VAL . 16.2 tp 178.61 -45.61 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.157 -1.202 . . . . 1.69 109.672 179.777 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ASN . . . . . 0.558 ' O ' ' CB ' ' A' ' 46' ' ' ASP . 17.8 p-10 -46.49 131.42 11.01 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.045 -1.035 . . . . 2.12 109.725 -179.76 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ASP . . . . . 0.558 ' CB ' ' O ' ' A' ' 45' ' ' ASN . 0.7 OUTLIER 82.6 -45.43 0.15 Allowed 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.573 -0.704 . . . . 2.21 110.603 179.293 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.643 HG11 ' HE3' ' A' ' 20' ' ' LYS . 15.4 m -78.4 89.02 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 120.993 -1.067 . . . . 1.18 110.193 -179.301 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.805 ' HB ' HG22 ' A' ' 92' ' ' ILE . 0.1 OUTLIER -160.4 102.99 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.371 -0.83 . . . . 1.46 108.839 179.59 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 49' ' ' SER . . . . . 0.487 ' HB3' ' CG1' ' A' ' 22' ' ' VAL . 0.4 OUTLIER -139.34 -60.36 0.56 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.024 -1.048 . . . . 0.7 110.741 -179.34 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.493 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 56.7 p -95.02 130.2 41.79 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.841 -1.162 . . . . 0.55 109.95 -179.157 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.628 HG13 ' HA ' ' A' ' 18' ' ' LEU . 2.3 t -135.57 156.88 38.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.235 -0.916 . . . . 0.73 109.36 179.8 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' LYS . . . . . 0.556 ' HD2' ' CE1' ' A' ' 24' ' ' PHE . 3.8 mtpt -134.85 119.0 17.58 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.164 -0.96 . . . . 1.58 109.577 -179.86 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.485 ' O ' ' HB2' ' A' ' 77' ' ' SER . 57.6 t -90.65 145.63 7.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.146 -0.971 . . . . 0.59 109.349 179.811 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.467 ' O ' ' HA ' ' A' ' 77' ' ' SER . . . -78.74 167.61 53.0 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.795 -1.322 . . . . 0.43 109.795 -179.818 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.425 ' O ' ' C ' ' A' ' 56' ' ' ASN . 35.3 Cg_endo -76.97 173.96 13.63 Favored 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 122.701 2.268 . . . . 0.81 110.307 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ASN . . . . . 0.425 ' C ' ' O ' ' A' ' 55' ' ' PRO . 0.7 OUTLIER 43.63 26.86 0.13 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.261 -0.899 . . . . 2.08 109.285 -179.782 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.619 HG23 ' HA2' ' A' ' 14' ' ' GLY . 65.8 m -131.03 169.29 16.05 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.358 -0.839 . . . . 1.07 109.382 -179.563 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.654 ' O ' ' HD1' ' A' ' 60' ' ' PHE . 4.6 tttt -138.25 99.39 3.85 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.175 -0.953 . . . . 1.49 108.911 179.642 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.453 ' O ' ' HB2' ' A' ' 74' ' ' LEU . . . -91.77 129.07 37.81 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.237 -0.915 . . . . 0.29 110.042 -179.32 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.654 ' HD1' ' O ' ' A' ' 58' ' ' LYS . 0.0 OUTLIER -116.13 115.25 25.71 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.359 -0.838 . . . . 1.27 109.38 179.767 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 1.016 HD11 HD11 ' A' ' 72' ' ' ILE . 40.1 pt -99.26 144.66 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.266 -0.896 . . . . 0.91 109.107 179.8 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' PHE . . . . . 0.56 ' CE2' ' HB2' ' A' ' 71' ' ' PHE . 9.0 m-85 -116.7 102.33 9.34 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.262 -0.899 . . . . 1.35 109.838 -179.627 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' LYS . . . . . 0.473 ' O ' ' HB2' ' A' ' 64' ' ' ASP . 19.8 tttt -48.93 141.08 8.06 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.194 -0.941 . . . . 2.92 108.75 179.641 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.517 ' N ' ' OG ' ' A' ' 93' ' ' SER . 0.1 OUTLIER 72.25 166.07 0.3 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.399 -0.813 . . . . 1.42 109.133 -179.561 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 65' ' ' ASP . . . . . 0.472 ' O ' ' O ' ' A' ' 68' ' ' ASN . 2.6 m-20 -43.07 142.1 1.03 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.351 -0.843 . . . . 2.0 109.33 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' ARG . . . . . 0.45 ' HB2' ' CB ' ' A' ' 94' ' ' SER . 0.0 OUTLIER -54.68 -18.44 4.59 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.006 -1.059 . . . . 2.8 109.528 -179.884 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -74.01 -38.13 64.18 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.185 -0.947 . . . . 2.41 109.947 -179.746 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' ASN . . . . . 0.472 ' O ' ' O ' ' A' ' 65' ' ' ASP . 5.0 m-20 -140.01 171.76 13.73 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.025 -1.047 . . . . 1.84 109.688 -179.809 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' GLY . . . . . 0.49 ' HA3' ' HB2' ' A' ' 64' ' ' ASP . . . 115.45 -122.82 5.71 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.495 -1.442 . . . . 0.44 109.495 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.478 ' O ' ' HA ' ' A' ' 62' ' ' PHE . 9.7 t-20 -147.02 164.78 31.9 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.213 -1.169 . . . . 2.0 109.508 179.876 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' PHE . . . . . 0.56 ' HB2' ' CE2' ' A' ' 62' ' ' PHE . 14.3 p90 -129.23 149.32 51.08 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.308 -0.87 . . . . 1.4 109.851 -179.692 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 1.016 HD11 HD11 ' A' ' 61' ' ' ILE . 44.4 pt -144.91 145.89 20.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.319 -0.863 . . . . 1.46 109.095 179.48 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -106.52 143.43 34.63 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.247 -0.908 . . . . 2.74 110.007 -179.454 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.453 ' HB2' ' O ' ' A' ' 59' ' ' ALA . 3.7 mt -131.6 96.59 4.0 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.714 -0.847 . . . . 1.71 108.714 179.6 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.549 ' O ' ' CG ' ' A' ' 76' ' ' GLU . 12.7 pt-20 -71.72 167.93 18.85 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.275 -0.89 . . . . 2.08 110.019 -179.426 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' GLU . . . . . 0.549 ' CG ' ' O ' ' A' ' 75' ' ' GLU . 7.3 pt-20 47.59 179.98 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.696 0 CA-C-O 121.554 0.692 . . . . 2.16 110.306 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' SER . . . . . 0.485 ' HB2' ' O ' ' A' ' 53' ' ' VAL . 85.7 p -62.91 -173.18 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.42 -0.8 . . . . 1.42 109.827 -179.578 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' SER . . . . . 0.46 ' OG ' ' HB ' ' A' ' 53' ' ' VAL . 79.1 p -179.89 161.61 0.98 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.42 -0.8 . . . . 0.93 109.33 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -135.24 94.58 3.14 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.223 -0.923 . . . . 1.93 109.859 -179.807 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 1.092 HG11 HD21 ' A' ' 83' ' ' LEU . 54.4 t -94.71 71.26 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 O-C-N 121.381 -0.824 . . . . 0.71 109.203 179.72 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.464 ' O ' ' HB ' ' A' ' 22' ' ' VAL . 0.0 OUTLIER -59.01 -34.0 71.37 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.475 -0.765 . . . . 0.84 110.214 -179.568 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 82' ' ' ASP . . . . . 0.449 ' OD1' HG11 ' A' ' 22' ' ' VAL . 0.1 OUTLIER -127.74 141.01 51.71 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.041 -1.037 . . . . 2.19 110.184 -179.468 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 1.092 HD21 HG11 ' A' ' 80' ' ' VAL . 21.3 mt -126.43 21.31 7.23 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.412 -0.805 . . . . 0.94 109.342 179.609 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' THR . . . . . 0.532 ' CG2' ' OD1' ' A' ' 89' ' ' ASN . 1.2 p -59.96 -44.23 94.54 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.233 -0.917 . . . . 2.8 109.523 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.411 HG23 ' H ' ' A' ' 85' ' ' THR . 16.3 p -61.93 -32.15 72.54 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.305 -0.872 . . . . 5.62 109.538 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' ARG . . . . . 0.512 ' NE ' ' HA ' ' A' ' 86' ' ' ARG . 0.0 OUTLIER -71.0 -42.08 70.09 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.218 -0.926 . . . . 5.54 109.739 -179.75 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.488 ' HB2' ' O ' ' A' ' 86' ' ' ARG . 19.9 t-20 172.2 66.11 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.142 -0.974 . . . . 3.6 109.921 179.887 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.476 ' O ' ' O ' ' A' ' 87' ' ' ASN . 0.1 OUTLIER 57.67 116.08 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.233 -0.917 . . . . 2.19 109.893 179.551 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 89' ' ' ASN . . . . . 0.532 ' OD1' ' CG2' ' A' ' 84' ' ' THR . 0.3 OUTLIER -45.88 162.33 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.218 -0.926 . . . . 2.11 109.6 179.76 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 90' ' ' ASP . . . . . 0.703 ' O ' ' HB3' ' A' ' 91' ' ' ALA . 33.9 m-20 61.65 134.61 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.071 -1.018 . . . . 1.05 109.637 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.703 ' HB3' ' O ' ' A' ' 90' ' ' ASP . . . 75.91 35.79 0.48 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.192 -0.943 . . . . 1.31 110.092 179.62 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.805 HG22 ' HB ' ' A' ' 48' ' ' VAL . 0.1 OUTLIER -45.48 -90.91 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 120.96 -1.087 . . . . 1.17 108.883 179.591 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 93' ' ' SER . . . . . 0.618 ' H ' HG23 ' A' ' 92' ' ' ILE . 0.4 OUTLIER 174.69 -83.33 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.815 -1.178 . . . . 1.23 109.833 179.546 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 94' ' ' SER . . . . . 0.468 ' HB3' ' HA ' ' A' ' 36' ' ' TYR . 4.4 m -143.22 145.69 33.0 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.29 -0.881 . . . . 0.49 109.525 -179.673 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.944 HG22 HG22 ' A' ' 61' ' ' ILE . 0.5 OUTLIER -132.5 134.19 59.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.333 -0.854 . . . . 0.65 109.383 179.792 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 96' ' ' ILE . . . . . 0.432 HG23 ' OD1' ' A' ' 34' ' ' ASN . 22.5 mt -120.52 146.82 24.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.475 0 O-C-N 121.285 -0.884 . . . . 0.42 109.312 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.77 HG22 ' O ' ' A' ' 33' ' ' GLY . 2.5 m -116.89 118.85 60.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.178 -0.951 . . . . 1.15 109.423 179.862 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -140.47 129.85 23.9 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.232 -0.918 . . . . 0.5 109.578 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 80.2 p -75.73 168.54 19.83 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.203 -0.936 . . . . 0.86 109.528 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 38.4 t80 -80.47 141.43 35.23 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.346 -0.846 . . . . 4.37 109.518 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.414 ' O ' ' C ' ' A' ' 102' ' ' SER . 0.4 OUTLIER -158.93 155.84 28.39 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.292 -0.88 . . . . 5.04 109.449 179.973 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.414 ' C ' ' O ' ' A' ' 101' ' ' GLU . 7.3 p -44.49 145.17 0.89 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.261 -0.899 . . . . 5.9 109.424 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.504 0 CA-C-O 117.983 -1.008 . . . . 6.97 109.472 -179.961 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.48 -0.563 . . . . 5.48 109.48 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 12.4 p -161.08 170.67 20.01 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.245 -0.909 . . . . 2.46 109.597 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.876 ' CG1' HG22 ' A' ' 31' ' ' VAL . 4.7 t -85.69 165.17 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.298 -0.877 . . . . 1.39 109.409 179.906 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.417 ' N ' HG12 ' A' ' 3' ' ' VAL . 0.7 OUTLIER -116.67 115.92 26.57 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.273 -0.892 . . . . 0.84 109.527 -179.944 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.511 ' HD3' ' N ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -72.89 154.51 40.55 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.225 -0.922 . . . . 1.99 109.315 179.87 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.511 ' N ' ' HD3' ' A' ' 5' ' ' LYS . . . 95.59 100.19 1.82 Allowed Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.161 -1.576 . . . . 0.42 109.161 -179.639 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.691 HG13 ' OG ' ' A' ' 28' ' ' SER . 4.1 m -92.5 173.0 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.242 -1.152 . . . . 0.57 109.913 -179.624 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 3.6 t -111.22 -156.18 0.58 Allowed 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.441 -0.787 . . . . 1.82 109.454 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -56.12 -68.48 1.67 Allowed Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.46 -1.456 . . . . 2.4 109.46 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -145.32 139.49 15.04 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.258 -1.142 . . . . 4.06 109.432 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.577 ' HB3' ' CD1' ' A' ' 17' ' ' PHE . 36.1 Cg_endo -78.45 141.07 17.57 Favored 'Trans proline' 0 C--N 1.311 -1.396 0 C-N-CA 122.443 2.095 . . . . 2.55 110.634 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . 0.933 ' HB1' ' HE3' ' A' ' 13' ' ' LYS . . . -148.49 173.28 13.28 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.395 -0.816 . . . . 1.35 109.595 179.681 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.933 ' HE3' ' HB1' ' A' ' 12' ' ' ALA . 0.0 OUTLIER 43.44 91.73 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.281 -0.887 . . . . 3.78 110.37 179.613 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.619 ' HA2' HG23 ' A' ' 57' ' ' THR . . . 47.04 34.06 7.35 Favored Glycine 0 N--CA 1.493 2.465 0 N-CA-C 110.863 -0.895 . . . . 0.54 110.863 178.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.567 ' HB2' ' N ' ' A' ' 12' ' ' ALA . 47.5 mt-10 -116.56 137.64 52.02 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.864 -1.374 . . . . 2.06 109.588 179.406 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 43.1 t -134.13 133.19 55.91 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.39 -0.819 . . . . 0.31 109.467 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.586 ' CD2' ' HB ' ' A' ' 7' ' ' VAL . 10.3 m-30 -107.19 111.79 24.36 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.315 -0.865 . . . . 1.26 109.526 179.892 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.903 HD11 HD13 ' A' ' 95' ' ' ILE . 4.9 mp -82.95 163.86 20.78 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.273 -0.892 . . . . 0.67 109.155 179.663 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . 0.525 ' HB3' ' HA ' ' A' ' 24' ' ' PHE . 13.8 m-85 -147.48 112.77 5.56 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.198 -0.938 . . . . 1.4 109.928 -179.659 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.643 ' HE3' HG11 ' A' ' 47' ' ' VAL . 15.8 tttt -46.33 141.78 3.31 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.285 -0.884 . . . . 2.43 108.762 179.379 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' HIS . . . . . 0.561 ' CD2' ' HD3' ' A' ' 20' ' ' LYS . 12.5 m-70 64.09 166.35 0.15 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.102 -0.998 . . . . 0.76 109.003 -179.647 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 1.066 HG23 ' ND2' ' A' ' 23' ' ' ASN . 33.9 m -82.65 -177.82 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.165 -0.959 . . . . 0.77 110.422 -179.432 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 1.066 ' ND2' HG23 ' A' ' 22' ' ' VAL . 10.5 p30 40.8 51.8 3.14 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.809 -0.557 . . . . 2.15 110.569 179.601 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.556 ' CE1' ' HD2' ' A' ' 52' ' ' LYS . 3.0 m-85 35.55 49.29 0.5 Allowed 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.628 -0.67 . . . . 2.93 110.625 179.085 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . 0.496 ' HB2' ' OD1' ' A' ' 23' ' ' ASN . 7.5 tt0 -108.04 71.95 0.83 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.946 -1.096 . . . . 1.73 109.5 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 161.3 -179.25 36.84 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.46 -1.456 . . . . 0.5 109.46 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.605 ' HB3' ' CZ3' ' A' ' 29' ' ' TRP . 5.4 m-20 -52.39 163.03 0.45 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.266 -1.138 . . . . 1.66 109.465 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . 0.691 ' OG ' HG13 ' A' ' 7' ' ' VAL . 9.0 p -124.02 139.55 53.84 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.253 -0.904 . . . . 0.46 109.759 -179.796 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' TRP . . . . . 0.605 ' CZ3' ' HB3' ' A' ' 27' ' ' ASP . 2.3 m-90 -115.4 149.75 37.48 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.271 -0.893 . . . . 3.71 109.496 179.86 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -118.71 118.7 32.34 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.244 -0.91 . . . . 1.67 109.723 -179.75 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.876 HG22 ' CG1' ' A' ' 3' ' ' VAL . 1.8 t -126.5 115.85 43.35 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.339 -0.85 . . . . 0.69 109.284 179.675 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.506 ' CG2' ' HG2' ' A' ' 15' ' ' GLU . 3.4 p -114.11 39.97 2.61 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.248 -0.907 . . . . 1.62 109.153 179.752 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.77 ' O ' HG22 ' A' ' 97' ' ' VAL . . . -154.68 -112.32 0.44 Allowed Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.502 -1.439 . . . . 2.05 109.502 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.581 ' ND2' HG23 ' A' ' 96' ' ' ILE . 11.5 m120 -138.68 140.57 38.85 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.368 -1.078 . . . . 1.85 108.972 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.726 HG21 HG22 ' A' ' 3' ' ' VAL . 41.0 t -146.93 100.15 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.02 -1.05 . . . . 1.11 109.809 -179.829 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . 0.471 ' O ' ' O ' ' A' ' 37' ' ' ASP . 4.2 p90 -105.66 150.87 25.05 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.224 -0.922 . . . . 4.46 109.058 179.62 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.471 ' O ' ' O ' ' A' ' 36' ' ' TYR . 1.4 m-20 48.5 96.93 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.148 -0.97 . . . . 1.2 109.303 -179.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.624 ' CE2' HG23 ' A' ' 92' ' ' ILE . 1.7 p90 -106.63 46.63 0.92 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.182 -0.949 . . . . 4.62 109.925 -179.603 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.537 ' HA ' ' CB ' ' A' ' 45' ' ' ASN . 22.9 ptt180 -82.67 -41.22 19.65 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.134 -0.979 . . . . 3.77 109.655 179.871 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . 0.485 ' N ' ' HG3' ' A' ' 39' ' ' ARG . 0.9 OUTLIER -112.01 59.24 0.63 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.078 -1.014 . . . . 1.97 109.627 179.974 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.736 ' O ' HG12 ' A' ' 41' ' ' VAL . 74.3 t -105.49 8.34 9.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.145 -0.972 . . . . 1.21 109.706 -179.873 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 65.39 79.34 0.25 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.137 -0.977 . . . . 2.08 109.578 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . 0.573 ' O ' ' CZ2' ' A' ' 29' ' ' TRP . . . 82.31 74.99 1.16 Allowed Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.861 -1.295 . . . . 1.77 109.861 179.815 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.536 ' HA ' ' CG2' ' A' ' 47' ' ' VAL . 16.2 tp 178.61 -45.61 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.157 -1.202 . . . . 1.69 109.672 179.777 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . 0.558 ' O ' ' CB ' ' A' ' 46' ' ' ASP . 17.8 p-10 -46.49 131.42 11.01 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.045 -1.035 . . . . 2.12 109.725 -179.76 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . 0.558 ' CB ' ' O ' ' A' ' 45' ' ' ASN . 0.7 OUTLIER 82.6 -45.43 0.15 Allowed 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.573 -0.704 . . . . 2.21 110.603 179.293 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.643 HG11 ' HE3' ' A' ' 20' ' ' LYS . 15.4 m -78.4 89.02 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 120.993 -1.067 . . . . 1.18 110.193 -179.301 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.805 ' HB ' HG22 ' A' ' 92' ' ' ILE . 0.1 OUTLIER -160.4 102.99 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.371 -0.83 . . . . 1.46 108.839 179.59 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . 0.487 ' HB3' ' CG1' ' A' ' 22' ' ' VAL . 0.4 OUTLIER -139.34 -60.36 0.56 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.024 -1.048 . . . . 0.7 110.741 -179.34 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.493 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 56.7 p -95.02 130.2 41.79 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.841 -1.162 . . . . 0.55 109.95 -179.157 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.628 HG13 ' HA ' ' A' ' 18' ' ' LEU . 2.3 t -135.57 156.88 38.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.235 -0.916 . . . . 0.73 109.36 179.8 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . 0.556 ' HD2' ' CE1' ' A' ' 24' ' ' PHE . 3.8 mtpt -134.85 119.0 17.58 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.164 -0.96 . . . . 1.58 109.577 -179.86 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.485 ' O ' ' HB2' ' A' ' 77' ' ' SER . 57.6 t -90.65 145.63 7.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.146 -0.971 . . . . 0.59 109.349 179.811 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.467 ' O ' ' HA ' ' A' ' 77' ' ' SER . . . -78.74 167.61 53.0 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.795 -1.322 . . . . 0.43 109.795 -179.818 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.425 ' O ' ' C ' ' A' ' 56' ' ' ASN . 35.3 Cg_endo -76.97 173.96 13.63 Favored 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 122.701 2.268 . . . . 0.81 110.307 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . 0.425 ' C ' ' O ' ' A' ' 55' ' ' PRO . 0.7 OUTLIER 43.63 26.86 0.13 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.261 -0.899 . . . . 2.08 109.285 -179.782 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.619 HG23 ' HA2' ' A' ' 14' ' ' GLY . 65.8 m -131.03 169.29 16.05 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.358 -0.839 . . . . 1.07 109.382 -179.563 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.654 ' O ' ' HD1' ' A' ' 60' ' ' PHE . 4.6 tttt -138.25 99.39 3.85 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.175 -0.953 . . . . 1.49 108.911 179.642 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.453 ' O ' ' HB2' ' A' ' 74' ' ' LEU . . . -91.77 129.07 37.81 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.237 -0.915 . . . . 0.29 110.042 -179.32 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.654 ' HD1' ' O ' ' A' ' 58' ' ' LYS . 0.0 OUTLIER -116.13 115.25 25.71 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.359 -0.838 . . . . 1.27 109.38 179.767 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 1.016 HD11 HD11 ' A' ' 72' ' ' ILE . 40.1 pt -99.26 144.66 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.266 -0.896 . . . . 0.91 109.107 179.8 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . 0.56 ' CE2' ' HB2' ' A' ' 71' ' ' PHE . 9.0 m-85 -116.7 102.33 9.34 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.262 -0.899 . . . . 1.35 109.838 -179.627 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . 0.473 ' O ' ' HB2' ' A' ' 64' ' ' ASP . 19.8 tttt -48.93 141.08 8.06 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.194 -0.941 . . . . 2.92 108.75 179.641 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.517 ' N ' ' OG ' ' A' ' 93' ' ' SER . 0.1 OUTLIER 72.25 166.07 0.3 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.399 -0.813 . . . . 1.42 109.133 -179.561 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' ASP . . . . . 0.472 ' O ' ' O ' ' A' ' 68' ' ' ASN . 2.6 m-20 -43.07 142.1 1.03 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.351 -0.843 . . . . 2.0 109.33 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . 0.45 ' HB2' ' CB ' ' A' ' 94' ' ' SER . 0.0 OUTLIER -54.68 -18.44 4.59 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.006 -1.059 . . . . 2.8 109.528 -179.884 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -74.01 -38.13 64.18 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.185 -0.947 . . . . 2.41 109.947 -179.746 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' ASN . . . . . 0.472 ' O ' ' O ' ' A' ' 65' ' ' ASP . 5.0 m-20 -140.01 171.76 13.73 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.025 -1.047 . . . . 1.84 109.688 -179.809 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . 0.49 ' HA3' ' HB2' ' A' ' 64' ' ' ASP . . . 115.45 -122.82 5.71 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.495 -1.442 . . . . 0.44 109.495 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.478 ' O ' ' HA ' ' A' ' 62' ' ' PHE . 9.7 t-20 -147.02 164.78 31.9 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.213 -1.169 . . . . 2.0 109.508 179.876 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . 0.56 ' HB2' ' CE2' ' A' ' 62' ' ' PHE . 14.3 p90 -129.23 149.32 51.08 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.308 -0.87 . . . . 1.4 109.851 -179.692 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 1.016 HD11 HD11 ' A' ' 61' ' ' ILE . 44.4 pt -144.91 145.89 20.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.319 -0.863 . . . . 1.46 109.095 179.48 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -106.52 143.43 34.63 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.247 -0.908 . . . . 2.74 110.007 -179.454 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.453 ' HB2' ' O ' ' A' ' 59' ' ' ALA . 3.7 mt -131.6 96.59 4.0 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.714 -0.847 . . . . 1.71 108.714 179.6 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.549 ' O ' ' CG ' ' A' ' 76' ' ' GLU . 12.7 pt-20 -71.72 167.93 18.85 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.275 -0.89 . . . . 2.08 110.019 -179.426 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . 0.549 ' CG ' ' O ' ' A' ' 75' ' ' GLU . 7.3 pt-20 47.59 179.98 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.696 0 CA-C-O 121.554 0.692 . . . . 2.16 110.306 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . 0.485 ' HB2' ' O ' ' A' ' 53' ' ' VAL . 85.7 p -62.91 -173.18 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.42 -0.8 . . . . 1.42 109.827 -179.578 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . 0.46 ' OG ' ' HB ' ' A' ' 53' ' ' VAL . 79.1 p -179.89 161.61 0.98 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.42 -0.8 . . . . 0.93 109.33 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -135.24 94.58 3.14 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.223 -0.923 . . . . 1.93 109.859 -179.807 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 1.092 HG11 HD21 ' A' ' 83' ' ' LEU . 54.4 t -94.71 71.26 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 O-C-N 121.381 -0.824 . . . . 0.71 109.203 179.72 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.464 ' O ' ' HB ' ' A' ' 22' ' ' VAL . 0.0 OUTLIER -59.01 -34.0 71.37 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.475 -0.765 . . . . 0.84 110.214 -179.568 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . 0.449 ' OD1' HG11 ' A' ' 22' ' ' VAL . 0.1 OUTLIER -127.74 141.01 51.71 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.041 -1.037 . . . . 2.19 110.184 -179.468 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 1.092 HD21 HG11 ' A' ' 80' ' ' VAL . 21.3 mt -126.43 21.31 7.23 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.412 -0.805 . . . . 0.94 109.342 179.609 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . 0.532 ' CG2' ' OD1' ' A' ' 89' ' ' ASN . 1.2 p -59.96 -44.23 94.54 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.233 -0.917 . . . . 2.8 109.523 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.411 HG23 ' H ' ' A' ' 85' ' ' THR . 16.3 p -61.93 -32.15 72.54 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.305 -0.872 . . . . 5.62 109.538 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . 0.512 ' NE ' ' HA ' ' A' ' 86' ' ' ARG . 0.0 OUTLIER -71.0 -42.08 70.09 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.218 -0.926 . . . . 5.54 109.739 -179.75 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.488 ' HB2' ' O ' ' A' ' 86' ' ' ARG . 19.9 t-20 172.2 66.11 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.142 -0.974 . . . . 3.6 109.921 179.887 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.476 ' O ' ' O ' ' A' ' 87' ' ' ASN . 0.1 OUTLIER 57.67 116.08 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.233 -0.917 . . . . 2.19 109.893 179.551 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . 0.532 ' OD1' ' CG2' ' A' ' 84' ' ' THR . 0.3 OUTLIER -45.88 162.33 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.218 -0.926 . . . . 2.11 109.6 179.76 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . 0.703 ' O ' ' HB3' ' A' ' 91' ' ' ALA . 33.9 m-20 61.65 134.61 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.071 -1.018 . . . . 1.05 109.637 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.703 ' HB3' ' O ' ' A' ' 90' ' ' ASP . . . 75.91 35.79 0.48 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.192 -0.943 . . . . 1.31 110.092 179.62 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.805 HG22 ' HB ' ' A' ' 48' ' ' VAL . 0.1 OUTLIER -45.48 -90.91 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 120.96 -1.087 . . . . 1.17 108.883 179.591 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . 0.618 ' H ' HG23 ' A' ' 92' ' ' ILE . 0.4 OUTLIER 174.69 -83.33 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.815 -1.178 . . . . 1.23 109.833 179.546 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . 0.468 ' HB3' ' HA ' ' A' ' 36' ' ' TYR . 4.4 m -143.22 145.69 33.0 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.29 -0.881 . . . . 0.49 109.525 -179.673 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.944 HG22 HG22 ' A' ' 61' ' ' ILE . 0.5 OUTLIER -132.5 134.19 59.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.333 -0.854 . . . . 0.65 109.383 179.792 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . 0.581 HG23 ' ND2' ' A' ' 34' ' ' ASN . 22.5 mt -120.52 146.82 24.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.475 0 O-C-N 121.285 -0.884 . . . . 0.42 109.312 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.77 HG22 ' O ' ' A' ' 33' ' ' GLY . 2.5 m -116.89 118.85 60.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.178 -0.951 . . . . 1.15 109.423 179.862 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -140.47 129.85 23.9 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.232 -0.918 . . . . 0.5 109.578 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 80.2 p -75.73 168.54 19.83 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.203 -0.936 . . . . 0.86 109.528 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 38.4 t80 -80.47 141.43 35.23 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.346 -0.846 . . . . 4.37 109.518 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.414 ' O ' ' C ' ' A' ' 102' ' ' SER . 0.4 OUTLIER -158.93 155.84 28.39 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.292 -0.88 . . . . 5.04 109.449 179.973 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.414 ' C ' ' O ' ' A' ' 101' ' ' GLU . 7.3 p -44.49 145.17 0.89 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.261 -0.899 . . . . 5.9 109.424 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.504 0 CA-C-O 117.983 -1.008 . . . . 6.97 109.472 -179.961 . . . . . . . . 0 0 . 1 stop_ save_